We have performed a pilot study of MDR-1 gene transfer chain reaction (PCR) for vector-derived MDR-1 cDNA in patients receiving CD34-selected peripheral blood stem sequence in all cases. Analysis of peripheral blood and cell (PBSC) transplant for lymphoma. To ensure minimum bone marrow cells after transplant has, however, shown engraftment thresholds and facilitate CD34 purification, no evidence of in vivo gene transfer with a follow-up of 12, mobilisation of Ͼ2 × 10 6 CD34 cells/kg was a condition for 15 and 18 months. The effect of MDR-1 substrate drugs recruitment. Of 11 patients counselled for study entry, only
Introduction
Dose escalation with autologous stem cell support is an accepted form of salvage therapy in selected patients with Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL). [1] [2] [3] For such patients treated in this way a 5-year progression-free survival of approximately 50 and 46% can be expected. Individuals who relapse after highdose therapy, however, have a poor outlook due to a combination of disease chemoresistance, cumulative nonhaematological toxicity from previous therapy and sensitivity to further myelosuppression. In order to enhance resistance to myelotoxic drugs after high-dose therapy we sought to transfer the human multidrug resistance gene (MDR-1) into the peripheral blood stem cells of patients undergoing high-dose therapy for lymphoma using an amphotropic retroviral vector.
Gene transfer into human haemopoietic stem cells using the current generation of amphotropic retroviral vectors is known to be a highly inefficient process. Recent clinical studies employing a variety of transduction pro-tocols, but all using vectors based on Moloney murine leukaemia virus (MoMLV), have reported the long-term detection of proviral DNA in between one in 10 3 and one in 10 4 circulating blood cells. [4] [5] [6] Transfer of a drug resistance gene such as MDR-1, whose product P-glycoprotein (PGP) is an ATP-dependent membrane efflux transporter for several chemotherapeutic agents, might improve this situation by allowing in vivo selection of transduced cells. In addition, transduction of stem cells with MDR-1 during PBSC transplant for lymphoma might render the patient more resistant to the myelotoxic effects of antilymphoma drugs, many of which are MDR-1 substrates. Although nonhaematological toxicity would not be affected by this approach, there might be some clinical benefit by allowing post-transplant consolidation chemotherapy or more effective palliative therapy to be given in the event of relapse.
The validity of this approach has been previously demonstrated in vitro and in a murine bone marrow transplant model. Retrovirally mediated MDR-1 gene transfer into human haemopoietic progenitors may be readily achieved by prestimulating purified CD34 cells with cytokines and results in a degree of in vitro resistance to MDR-1 substrates such as colchicine and paclitaxel. [7] [8] [9] In vivo transplantation studies in mice demonstrated longterm engraftment of human MDR-1 expressing cells which increased in number following exposure to paclitaxel. 10, 11 A major limitation of the currently available retroviral vectors is their requirement for target cells to transit the cell cycle in order for proviral integration to occur. 12, 13 Mobilised peripheral blood stem cells are generally quiescent and are thus intrinsically refractory to transduction by such vectors.
14 Attempts to improve transduction efficiency by using cocktails of haemopoietic growth to induce entry into the cell cycle resulted in only transient marking of cells in vivo, suggesting that retroviral integration had occurred in committed progenitors rather than stem cells. 5 Similar results were recently reported using autologous stroma. 15 Ex vivo exposure to cytokines may impair engraftment so that gene transfer protocols involving growth factor prestimulation may be unsuccessful because these cells are competed out by unmanipulated cells. 16 We therefore sought to avoid extensive ex vivo manipulation and the use of haemopoietic growth factors by exposing freshly purified mobilised CD34 cells to retroviral supernatant for a short period then cryopreserving the cells and reinfusing after ablative chemotherapy. The rationale for this approach was to deliver 'virally loaded' CD34 cells to the ablated bone marrow microenvironment where the conditions would most favour induction of stem cell division. Providing the internalised provirus remains stable until cell division occurs, transduction should occur in vivo thus avoiding potential problems associated with ex vivo culture and manipulation.
Results
Recruitment into the study During the study period, 11 patients fulfilled the initial eligibility criteria and were offered entry into the trial. Only five patients achieved the mobilisation thresholds targets of Ͼ2 × 10 6 mobilised CD34 + cells in a single apheresis and a further two declined entry.
CD34 purification and retroviral transduction
In keeping with previous experience, variable results were obtained in CD34 selections with CD34 recoveries after purification of 10.7, 14.3 and 77% and yields of 0.5, 0.7 and 3.5 × 10 6 /kg in patients 1, 2 and 3, respectively. Following purification, the harvest product was exposed to A12M1 supernatant as described below. PCR analyses of progenitor colonies from the transduced CD34 cells showed one of 35, none of 33 and none of 44 positive for MDR-1 cDNA sequence in patients 1, 2 and 3. Aliquots of post-transduction samples thawed and then washed to remove DNA derived from the producer cell line were positive for the MDR-1 cDNA in all cases (Figure 1 ).
Haematological reconstitution and follow-up
The time taken to reach Ͼ0.5 × 10 9 /l neutrophils and an unsupported platelet count of Ͼ50 × 10 9 /l is known to be related to the CD34 dose administered. In view of the relatively prolonged time (60 days) for platelet regeneration in patient 1, back-up unmanipulated PBSCs were given to patient 2 (who had 0.7 × 10 6 CD34 cells/kg after manipulation) 24 h after reinfusion of the transduced cells. When the infused CD34 cell dose is taken into account, the recovery times of patients receiving unmanipulated PBSCs, purified CD34 cells or CD34 cells exposed to the amphotropic retroviral vector are similar ( Figure 2 ). Nested PCR analysis (sensitivity of 1:10 000) performed on peripheral blood mononuclear cells following engraftment and at 3-6 monthly intervals until the present time have been uniformly negative for the vectorderived MDR-1 cDNA sequence. Since levels of transduction in bone marrow (BM) progenitors and CD34 cells have been reported to be higher than in peripheral blood, 6 bone marrow aspirates were obtained from all three patients at 3 months following transplantation. PCR analysis of BM mononuclear cells, CD34 purified cells and progenitor cells was negative for the transgene. All three patients remain haematologically normal and in complete remission at 18, 15 and 12 months following transplantation so that we have not yet tested the potential of MDR-1 substrate drugs to select for survival of MDR-transduced cells.
Discussion
This study set out to determine the feasibility of using an amphotropic retroviral vector to transfer the MDR-1 gene into peripheral blood stem cells of poor prognosis patients undergoing high-dose therapy for relapsed and resistant lymphoma. Although the number of patients is small, no adverse effects were observed. In particular, when infused CD34 dose is taken into account, haematological reconstitution was similar to that seen with unpurified PBSCs and purified untransduced CD34 cells, although one of the patients did receive unmanipulated back-up cells.
The patient population in this study was chosen to include those at high risk of relapse both because of the experimental nature of the procedure and to allow future assessment of any selective advantage for transduced cells when chemotherapy for relapse is given. It is well recognised that PBSC mobilisation is adversely influenced by previous therapy however, and this is compounded by the need to collect the additional cells required to allow for the losses associated with CD34 purification. 17 Thus, the majority of eligible patients (six of 11) failed to mobilise adequate numbers of stem cells to allow a margin for safety during subsequent manipulations. Experimental studies of this type involving manipulation of CD34 cells are therefore least likely to be feasible in the high-risk patients for whom they are most readily justified. One possible solution will be to consider transducing purified cells obtained from several harvests; however, the logistical and financial constraints of such an approach are considerable. An alternative possibility is to purify and transduce bone marrow cells when a PBSC harvest is poor but a recent analysis from our centre indicates that when stem cell mobilisation is poor, this usually reflects a poor bone marrow reserve. 18 Although clear evidence for the presence of vectorderived MDR-1 cDNA sequence was seen in the CD34-enriched cells after incubation with the retroviral vector, no in vivo evidence of gene transfer has so far been obtained. A number of factors might explain this finding. First, even with purified CD34 cells only a low ratio of virus to target cells was possible using the vector employed in this study. Second, the amphotropic retroviral receptor is expressed at low levels on CD34 cells, 19, 20 a finding that would presumably further compromise the efficiency of viral uptake. Despite these limitations, positive PCR signals were seen in all three patients after incubation of unstimulated CD34 with retrovirus for 6 h. This most likely reflects preintegration proviral DNA since integration would not have occurred in mobilised peripheral blood CD34 cells which are known to be noncycling during short-term culture.
14 Integration would be dependent upon those cells containing proviral DNA rapidly entering the cell cycle on reinfusion into the patient. No such event has been detected in so far as no transduced blood or bone marrow cells have been detected in any of the patients after reinfusion. This may be because stem cell division did not occur rapidly enough following reinfusion for integration of the proviral DNA to occur or that transduced cells are present but at a level below the limit of detection. Proviral DNA does appear to survive the cryopreservation process since positive PCR signals were obtained with aliquots of CD34 cells frozen after exposure to the vector. Since all patients remain in remission we have so far not tested whether MDR substrate drugs will result in selection of transduced cells that are currently undetectable.
An alternative approach to that followed in the present study would be to prestimulate purified CD34 + cells with a cocktail of haemopoietic growth factors before retroviral transduction. In a study using the same MDR-1 vector as that used in the present study, this strategy resulted in transient marking of bone marrow cells in two of seven patients. 21 This presumably reflects marking of committed progenitor cells or competition from unmanipulated cells which were also administered to ensure prompt engraftment.
In conclusion, our study illustrates that gene therapy of adult patients with heavily pretreated diseases such as relapsed lymphoma will be limited by the difficulty in obtaining sufficient stem cells for the necessary in vitro manipulations. In addition, our results confirm previous reports demonstrating the inefficiency of transduction of adult human haemopoietic stem cells using amphotropic retroviral vectors. 5, 15 The most likely reason for this is the requirement for target cells to undergo division before proviral integration can take place although other factors such as viral titre and receptor density may also have contributed. Improvements in vector design such as the use of alternative receptors to target specific cell types or the ability to transduce nondividing cells, as well as advances in the understanding of the factors controlling stem cell proliferation and engraftment, will be required to improve this situation.
Patients and methods
Patients studied All patients aged 16-60 years, referred to University College London Hospitals for high-dose therapy of relapsed Hodgkin's disease or high-grade NHL between November 1995 and July 1996 were considered for entry into the study. A retrospective analysis of follow-up data showed that the presence of a large (Ͼ10 cm) tumour mass, more than three lines of previous therapy, B symptoms and, in the case of Hodgkin's disease, resistance to conventional chemotherapy predicted for a Ͼ66% risk of relapse within 3 years of high-dose therapy. The last condition did not apply to NHL since resistance to conventional chemotherapy is associated with a poor prognosis and such patients are generally not offered high-dose therapy. Since we wished to test the effects of MDR-1 effluxed drugs following relapse, these criteria were used to select high-risk patients for entry into the study.
We have previously reported that administration of more than 1 × 10 6 CD34 cells/kg is associated with reliable haemopoietic reconstitution and that CD34 purification using the Ceprate SC system (CellPro, Bothell, WA, USA) results in average cell losses of 50%. 17 Patients were thus required to mobilise Ͼ2 × 10 6 CD34 cells/kg before entering the study.
The study was approved by a local research and ethics committee as well as the UK national Gene Therapy Advisory Committee and commenced in November 1995.
Mobilisation and CD34 selection
Peripheral blood stem cells were harvested and collected using previously published protocols. 22, 23 Briefly, patients received chemotherapy with either cyclophosphamide 1.5 g/m 2 (patients 1 and 2) or the ESHAP regimen (etoposide 40 mg/m 2 for 4 days, methylprednisolone 500 mg daily, cytarabine 2 g/m 2 and cisplatin 25 mg/m 2 daily for 4 days) 24 followed by a single daily vial of G-CSF (lenograstim, 263 g/vial) commencing 24 h after the chemotherapy. Peripheral blood stem cells were harvested using a continuous flow cell separator when the recovery white cell count first exceeded 3 × 10 9 /l, usually days 8 and 15, respectively. In each case, harvests were performed on 3 consecutive days with a whole day's collection used for CD34 purification and transduction and the remainder cryopreserved without further processing as a back-up.
The apheresis product was subjected to CD34 purification using the Ceprate SC system (CellPro) according to the manufacturer's instructions. The CD34 and progenitor content of the purified cells was assessed as previously described. 25 
Retroviral vector and transduction protocol
The amphotropic retroviral producer cell line A12M1 26 which derives from the packaging cell GP+envAM12 27 and the MDR-1 vector pHaMDR-1 28 was used in these studies. Clinical grade supernatants (provided by Genetix Pharmaceuticals, Cambridge, MA, USA) were produced in Iscove's modified Dulbecco's medium (IMDM) with 20% fetal calf serum (Magenta, Rockville, MD, USA). The titre of these supernatants assayed on NIH3T3 fibroblasts by transfer of resistance to colchicine was 1-5 × 10 4 /ml. 29 The master cell bank and retroviral supernatants were shown to be free of contaminating replication competent retrovirus by Mus dunni and S+L− assay. 30, 31 Following CD34 selection, the enriched product was added to a 2 l intravenous feeding bag containing 1 l of retroviral supernatant and protamine sulphate 4 g/ml. The cells and virus were incubated for 6 h at 37°C then transferred to a COBE 2991 cell washer (COBE BCT, Lakewood, CO, USA) and washed with 3 l of tissue culture grade phosphate-buffered saline containing 1% human serum albumin. To assist in visualisation of the cell product during the washing process, 0.5 ml of autologous heparinised blood was added at this stage. Previous experiments had shown this procedure to remove viable free virus effectively (data not shown). Following washing, the cell product was concentrated by centrifugation to approximately 4.5 ml and an equal volume of cryopreservation solution added (tissue grade PBS, 15% dimethyl sulphoxide (Sigma, Poole, UK) and 8% HSA). The cells were transferred into two sterile cryopreservation vials (Nalgene, Rochester, NY, USA) and stored in a controlled rate freezing device (Cryo 1°C container, Nalgene) at −80°C until required. Samples of the spent supernatant (5% of the final volume) as well as post-transduction cells (1% of total cells) were saved separately for assessment of transduction and future testing for replication-competent retrovirus. Progenitor assays were performed on the post-transduction cell product to allow assessment of the proportion transduced using commercially prepared media (Stem Cell Technologies, Vancouver, BC, Canada). Progenitor colonies were picked from methylcellulose cultures at 14 days, washed once in PBS then lysed by incubation in 20 l of lysis buffer containing 60 g/ml proteinase K, 10 mmol/l Tris-Cl pH 8.3, 50 mmol/l KCl, 2.5 mmol/l MgCl 2 , 0.45% NP40 and 0.45% Tween 20 (Sigma) at 55°C for 1 h followed by 5 min at 95°C. A 5 l aliquot of this sample was amplified using primers GACAGCTATTCGAAGAGTGG and GGCATTGGCTTC-CTTGACAG, with 2.25 mmol/l MgCl 2 and an annealing temperature of 65°C. These primers span exons 11-13 of the MDR-1 gene resulting in a 684 bp genomic band which serves as a control for DNA extraction and a 243 bp cDNA band present additionally in transduced colonies.
Assays of transduction
Where cell number was limiting, such as with the posttransduction CD34 cells, DNA was extracted by PK lysis as described above. In other cases, where peripheral blood or bone marrow cells were being examined DNA was extracted using the 'DTAB-CTAB' method. 32 DNA was extracted using the same methods from control samples consisting of HL-60 cells transduced with the A12M1 vector diluted into untransduced cells. DNA from 1-2 × 10 5 cells (approximately 1 g) was amplified using nested primers: (1) TGACTACCAGGCTCGCCAAT and CCGTGCTGTAGCTGTCAATC, annealing temperature 62°C, MgCl 2 2.25 mmol/l; and (2) CCCATCATTGCAAT-AGCAGG and TCAAACTTCTGCTCCTGAGT, annealing temperature 58°C and MgCl 2 2.25 mmol/l. A 5% aliquot of the first round PCR was used as a template in the second round. These primers do not amplify the genomic sequence (because of the presence of an intron) and produce a 167 bp fragment from the vector-derived cDNA sequence. The sensitivity of this assay is 1:10 000 transduced cells (data not shown).
Peripheral stem cell transplantation and follow-up All patients received conditioning chemotherapy with the BEAM regimen (BCNU 300 mg/m 2 day 1, etoposide 400 mg/m 2 and Ara-C 200 mg/m 2 days 2-5, melphalan 140 mg/m 2 day 6). 2 Cryopreserved purified transduced CD34 cells were thawed and reinfused 24 h after the final chemotherapy. In view of the relatively long period to platelet recovery seen in patient 1, the decision was made to give additional unmanipulated PBSCs to patient 2 who after the various manipulations had below 1 × 10 6 CD34 cells/kg. G-CSF (filgrastim 5 g/kg/day) was administered from day 7 until recovery of neutrophil counts to Ͼ0.5 × 10 9 /l. Recovery data were compared with a group of 257 historical controls who had either received CD34-selected transplants (24) or unpurified PBSC (233). Samples of peripheral blood were cryopreserved for replication-competent retrovirus assay and also analysed for the vector-derived MDR cDNA sequence on recovery and at 3-6 monthly intervals thereafter. In addition, a bone marrow aspirate was performed at 3 months following transplant. PCR analysis for the MDR-1 cDNA was performed on bone marrow mononuclear cells, CD34 cells purified using the Ceprate LC system and cultured progenitors.
